Tag
Resident physicians demonstrate lower breast cancer screening rates compared to faculty, even in well-supported academic practices. Adjusting for patient and physician factors narrows, but does not eliminate, this gap, underscoring the need
Population-based testing for breast cancer pathogenic variants identified many women who would not have been flagged by clinical or polygenic risk models, supporting its role in risk-based screening.
The MASAI trial demonstrates that AI-supported mammography screening achieves higher sensitivity and non-inferior interval cancer rates compared to standard double reading, while maintaining specificity and significantly reducing radiologis
This review analyzes the J-START trial’s secondary findings, demonstrating that adjunctive ultrasonography significantly reduces the 11-year cumulative incidence of advanced breast cancer in women aged 40–49, particularly those with d
A prespecified secondary analysis of the J-START trial reveals that adding ultrasonography to mammography for women aged 40-49 significantly reduces the long-term cumulative incidence of advanced breast cancer, particularly in populations w
A CISNET modeling study demonstrates that mammography screening tailored to 5-year absolute invasive breast cancer risk reduces false-positive recalls by up to 23% while maintaining or improving mortality benefits compared to traditional ag
The WISDOM trial shows risk-based breast cancer screening using genetic and clinical data as a safe alternative to annual mammography, tailoring screening frequency by individual risk without increasing advanced cancer rates.
A Singapore trial shows simple mailed reminders effectively increase overdue mammogram screenings; additional incentives or digital interventions offer no significant benefit.
Eliminating a $45 fee for advanced breast cancer screening technology improves access and reduces health disparities, according to recent research.
